| Off-label indication | Number of patients | Stage disease | Number of previous treatment lines | Median treatment duration (cycles) | |
|---|---|---|---|---|---|
| Bendamustine | Non-Hodgkin’s lymphomas (NHL) without previous rituximab | 4 | II | 0 | 5 |
| Lenalidomide | Diffuse large B-cell non-Hodgkin’s lymphoma | 2 | IV | 3 | 4 |
| Doxorubicin liposomal | NHL | 5 | III | 0:3 patients 1:1patient >3:1 patient | 6 |
| Mercaptopurine | Histiocytosis X | 1 | III | 1 | 12 |
| Fotemustine | Glioblastoma | 15 | IV | 2 | 5 |
| Oligodendroglioma | 1 | III | 3 | 8 | |
| Astrocytoma | 1 | IV | 2 | 1 | |
| Bevazicumab | Glioblastoma | 6 | IV | 2 | 3 |
| Oligodendroglioma | 1 | IV | 1 | 3 | |
| Astrocytoma | 2 | III | 1 | 3 | |
| Ependymoma | 1 | IV | 2 | 5 | |